You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti - PD-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • +2 more
  • nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
  • Changchun, Ji Lin, China
    First Hospital of Jilin University
Aug 11, 2023

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Camrelizumab (anti-PD-1 inhibitor)
  • Apatinib (anti-VEGFR inhibitor)
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Profiling of Circulating Immune Cells to Uncover Response

Not yet recruiting
  • Melanoma
    • (no location specified)
    Nov 23, 2023

    NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • Alirocumab and Cemiplimab
    • (no location specified)
    Jan 31, 2023

    Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

    Not yet recruiting
    • Solid Tumor, Adult
    • +2 more
    • (no location specified)
    Dec 14, 2022

    Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy Trial (neoadjuvant anti-PD-1 (Keytruda) plus chemo)

    Not yet recruiting
    • Esophageal Squamous Cell Carcinoma
    • Neoadjuvant Chemoimmunotherapy
    • neoadjuvant anti-PD-1 (Keytruda) plus chemotherapy
    • (no location specified)
    Feb 14, 2023

    Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

    Not yet recruiting
    • Hepatocellular Carcinoma Non-resectable
    • transarterial therapies
    • (no location specified)
    Nov 27, 2022

    Advanced Breast Cancer, Breast Tumor Malignant Female Trial in Guangzhou (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

    Completed
    • Advanced Breast Cancer
    • Breast Neoplasm Malignant Female
    • AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital of Sun Yat-sen University
    Apr 11, 2023

    Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Low-Dose Decitabine plus anti-PD-1
    • Beijing, Beijing, China
      ChinaPLAGH
    Apr 18, 2023

    NPC Trial in Guangzhou (Sintilimab, IBI310)

    Active, not recruiting
    • NPC
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Oct 3, 2022

    Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

    Not yet recruiting
    • Colorectal Cancer
    • Serplulimab + FOLFOXIRI
    • Radiation therapy
    • (no location specified)
    Oct 24, 2023

    Generation ofArtificial Intelligence Algorithm Based on Analysis

    Not yet recruiting
    • Metastatic Melanoma
    • Photo
    • (no location specified)
    May 3, 2023

    Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

    Not yet recruiting
    • Lung Neoplasm
    • +2 more
    • Tumor samples
    • Bordeaux, France
      CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
    Aug 28, 2023

    Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Sep 2, 2023

    Esophageal Squamous Cell Carcinoma, Oligometastatic Disease Trial in Guangzhou (PD-1 combined with SBRT)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Oligometastatic Disease
    • PD-1 combined with SBRT
    • Guangzhou, Guangdong, China
      Mian Xi
    Dec 18, 2022

    Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
    Jan 30, 2023

    Esophagus Cancer, Bladder Cancer, Liver Cancer Trial (Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal

    Not yet recruiting
    • Esophagus Cancer
    • +4 more
    • Intravenous injection of P-IL-2
    • P-IL-2 plus Anti-PD-1 Monoclonal Antibody
    • (no location specified)
    Apr 24, 2023

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

    Not yet recruiting
    • Advanced Solid Tumors
    • LCB84
    • Anti-PD-1 monoclonal antibody
    • Los Angeles, California
    • +6 more
    Jul 4, 2023